Ventus Therapeutics deploys leading-edge structural biology and unique computational chemistry tools to discover novel small molecule medicines for challenging targets in immunology, inflammation, and neurology.


Others are building towards a future transformation of the drug development process…for Ventus, that future is already here.

Our proprietary drug discovery platform, ReSOLVE™, gives us unique insights into protein motion and the ability to create blueprints of optimal drug molecules, in a process that disrupts virtual screening and allows Ventus to transition from in silico to the lab quickly and efficiently.

We screened our first target in 2020 and nominated three development candidates in 2022: VENT-03, a potential first-in-class cGAS inhibitor; VENT-02, a brain-penetrant NLRP3 inhibitor; and VENT-01, a systemic NLRP3 inhibitor.

These programs exemplify our unique capabilities and ability to generate first-and best-in-class drugs for immunology targets with franchise potential, by addressing prevalent diseases with relevant unmet needs.